spironolactone has been researched along with Urinary Retention in 1 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Urinary Retention: Inability to empty the URINARY BLADDER with voiding (URINATION).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Montrella-Waybill, M | 1 |
| Clore, JN | 1 |
| Schoolwerth, AC | 1 |
| Watlington, CO | 1 |
1 other study available for spironolactone and Urinary Retention
| Article | Year |
|---|---|
Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor.
Topics: Adult; Blood Pressure; Dose-Response Relationship, Drug; Fludrocortisone; Humans; Hydrocortisone; Ki | 1991 |